Methamphetamine (METH) abuse continues to escalate and effective treatments are not currently available. METH interacts with the vesicular monoamine transporter-2 (VMAT2), promoting both dopamine (DA) release into the cytosol and reversal of the DA transporter to increase extracellular DA concentrations, which is thought to be associated with its abuse liability. The overall objective of this project is to provide a clinical candidate for the treatment of METH abuse. Recently, we identified a novel small molecule (GZ-793A), which potently and selectively inhibits DA uptake by VMAT2, inhibits METH-evoked DA release from synaptic striatal vesicles and slices, and exhibits selectivity does not interact with nicotinic receptors or DA transporters. Off-target evaluation at a cadre of neurotransmitter-related, steroid and ion channel sites, second messenger, prostaglandin, growth factor and hormones, brain/gut peptides and enzymes revealed outstanding selectivity. Translation to whole animals models revealed that GZ-793A specifically decreases METH self-administration without altering responding for sucrose, does not produce tolerance to the decrease in METH self- administration upon repeated administration, and decreases METH seeking in the cue-induced reinstatement. Acute GZ793A pretreatment also protects against the neurotoxic effects of METH as measured by striatal DA depletion. Although the physicochemical properties of GZ-793A are favorable in terms of druggability, GZ-793A has only 2-3% oral bioavailability, likely due to the presence of the hydroxyl functionalities in the molecule which are likely sites for high first-pass metabolism. Thus, new optimized analogs of GZ-793A are the focus of the current application with the goal of identifying analogs with the required pharmacological properties, druggability, increased oral bioavailability, and acceptable pharmacokinetic profile. Compounds with these characteristics would be high value preclinical candidates for advancement toward clinical trials as treatments for METH abuse. Thus, we propose to expand our existing molecular library of analogs by performing the final steps of optimization of GZ-793A to identify a high value preclinical candidate as a potential therapeutics for METH abuse. In future work, the best candidate will undergo comprehensive toxicological evaluation for subsequent preparation of an Investigational New Drug application to the FDA as a proposed treatment for methamphetamine abuse.
Currently, there is no pharmacotherapeutic available for methamphetamine abuse. The overall objective of this project is to provide a clinical candidate for the treatment of methamphetamine abuse. Recently, we identified a novel small molecule (GZ-793A), which potently and selectively interacts with the vesicular monoamine transporter-2 and which exhibits potency and specificity in decreasing responding for intravenous methamphetamine in an animal model of self-administration. We propose to expand our existing molecular library by performing the final steps of optimization of the chemical structure of GZ-793A with the aim of providing additional leads that are druggable, orally-bioavailable, high value preclinical candidates. The outcome of the proposed project is to bring the best candidate to comprehensive toxicological evaluation for preparation of an Investigational New Drug application to the FDA as a proposed treatment for methamphetamine abuse.
|Sviripa, Vitaliy M; Zhang, Wen; Balia, Andrii G et al. (2014) 2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2. J Med Chem 57:6083-91|
|Nickell, Justin R; Siripurapu, Kiran B; Vartak, Ashish et al. (2014) The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol 69:71-106|
|Hofford, Rebecca S; Darna, Mahesh; Wilmouth, Carrie E et al. (2014) Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function. Behav Brain Res 270:151-8|
|Zheng, Guangrong; Horton, David B; Penthala, Narsimha Reddy et al. (2013) Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse. Medchemcomm 4:564-568|
|Meyer, Andrew C; Neugebauer, Nichole M; Zheng, Guangrong et al. (2013) Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem 127:187-98|
|Wilmouth, Carrie E; Zheng, Guangrong; Crooks, Peter A et al. (2013) Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav 112:29-33|
|Penthala, Narsimha Reddy; Ponugoti, Purushothama Rao; Nickell, Justin R et al. (2013) Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Bioorg Med Chem Lett 23:3342-5|
|Ding, Derong; Nickell, Justin R; Deaciuc, Agripina G et al. (2013) Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake. Bioorg Med Chem 21:6771-7|